Evelo Biosciences, Inc. (EVLO)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -114.52 Million USD | 6.26% |
| 2021 | -122.17 Million USD | -30.44% |
| 2020 | -93.66 Million USD | -9.34% |
| 2019 | -85.66 Million USD | -59.06% |
| 2018 | -53.85 Million USD | -92.01% |
| 2017 | -28.04 Million USD | -110.37% |
| 2016 | -13.33 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -25.34 Million USD | -7.65% |
| 2023 Q3 | -12.36 Million USD | 41.41% |
| 2023 Q2 | -21.1 Million USD | 16.72% |
| 2022 Q2 | -30.56 Million USD | -2.34% |
| 2022 Q3 | -30.56 Million USD | -0.01% |
| 2022 FY | -114.52 Million USD | 6.26% |
| 2022 Q1 | -29.86 Million USD | -4.22% |
| 2022 Q4 | -23.54 Million USD | 22.98% |
| 2021 Q4 | -28.65 Million USD | 15.05% |
| 2021 Q1 | -28.19 Million USD | 2.94% |
| 2021 Q2 | -31.59 Million USD | -12.07% |
| 2021 FY | -122.17 Million USD | -30.44% |
| 2021 Q3 | -33.73 Million USD | -6.75% |
| 2020 Q3 | -20.92 Million USD | -1.31% |
| 2020 Q2 | -20.65 Million USD | 10.37% |
| 2020 Q4 | -29.05 Million USD | -38.84% |
| 2020 FY | -93.66 Million USD | -9.34% |
| 2020 Q1 | -23.04 Million USD | -1.96% |
| 2019 Q4 | -22.59 Million USD | -4.47% |
| 2019 Q2 | -20.94 Million USD | -3.16% |
| 2019 Q1 | -20.29 Million USD | -31.44% |
| 2019 FY | -85.66 Million USD | -59.06% |
| 2019 Q3 | -21.63 Million USD | -3.3% |
| 2018 Q2 | -15.14 Million USD | -44.25% |
| 2018 FY | -53.85 Million USD | -92.01% |
| 2018 Q4 | -15.44 Million USD | 2.61% |
| 2018 Q3 | -15.85 Million USD | -4.69% |
| 2018 Q1 | -10.5 Million USD | -28.95% |
| 2017 Q1 | -5.37 Million USD | 0.0% |
| 2017 Q2 | -6.36 Million USD | -18.45% |
| 2017 Q3 | -8.17 Million USD | -28.49% |
| 2017 Q4 | -8.14 Million USD | 0.37% |
| 2017 FY | -28.04 Million USD | -110.37% |
| 2016 FY | -13.33 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -14941.239% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -1226.772% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -272.458% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 7.725% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -612.321% |
| Better Therapeutics, Inc. | -39.76 Million USD | -188.046% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -507.055% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -523.176% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -219.81% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -217.557% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -4994.028% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | -53.205% |
| Galera Therapeutics, Inc. | -59.08 Million USD | -93.844% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -1812.524% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -437.837% |
| Molecular Templates, Inc. | -8.12 Million USD | -1309.737% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -654.601% |
| NexImmune, Inc. | -32.34 Million USD | -254.086% |
| Orgenesis Inc. | -55.36 Million USD | -106.873% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -353.339% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -146697.493% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -526.182% |
| Scopus BioPharma Inc. | -11.6 Million USD | -886.466% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 80.007% |
| Statera Biopharma, Inc. | -174.4 Million USD | 34.334% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -3091.945% |
| Trevena, Inc. | -40.28 Million USD | -184.264% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -201057.481% |
| Vaccinex, Inc. | -20.25 Million USD | -465.538% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -9588.337% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | -124.308% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -1372.602% |